A randomised placebo-controlled superiority trial of GLP-1 receptor agonist for the treatment of alcohol use disorder in people with chronic liver disease and obesity with embedded mechanistic study: Controlling Unhealthy Relationships with Both alcohol and obesity (CURB trial). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.